532
114202226014562110163
Ces8507936014570127174
Urol10497936014578115180208
2018;12827936014562121176230253
22(2):15617936014561121152210240262
106–11418497936014561116178241295343396
ORIGINÁLNÍ852207016996181224324367468561635735777
PRÁCE1667207016983165262348424
tů85089801313490
s963898013146
významnou1032898013154105151208256344401458515
inkontinencí157089801312784128184241272293349401458506526
byl2124898013160107129
také227689801313887131182
nízký.248589801315980123168218230
Navíc2743898013170118164186233
průměrný850104801316192149236288318376421
počet12941048013161119167217249
epizod15671048013153112133176231290
inkontinence1880104801312480125180238269290346398455502552
za2455104801314595
týden2573104801313484142194250
byl28471048013161107129
menší8501198013190142199237257
než11321198013159111154
jedna,1309119801312577136193240258
přestože1591119801316191142181214269311361
údaje19761198013159117165186237
také2236119801313684129179
naznačují,24401198013159106150208255303359380400417
že2880119801314696
téměř850134801313484172224253
30%11221348013154105198
účastníků13391348013158106154193226283304350407
zaznamenalo1765134801314594138195243331383440487509565
epizody23501348013153112133176231290338
inkon‑2711134801311975120175233265
tinence850149801313454110162218265315
v11821498013150
určitémokamžiku1250149801315888133153185234321397442491579621642686742
před2010149801316091140199
výchozím22271498013149100146202259299321408
stavem.2652149801314174122168219306324
Ve8501648013156105
studii979164801314882139198219240
EPIC12421648013159112132194
přibližně1466164801316193114173196216259317370
30%18591648013161113207
žen20891648013152103160
s22731648013148
OAB23511648013175135189
trpělo2563164801314172133186207265
ur‑2851164801316697125
gentní8501798013160112168199256277
inkontinencí1150179801312379123179236267288345397453501521
a16941798013150
50%17671798013154104197
trpělo1987179801313464124176198255
jakoukoli2265179801312370115170227271327349369
formou2657179801312985116205262319
inkontinencemoči850194801312378122177233263284339390446493542649705752772
(3).164519480131247295109
Podobně17711948013155109167223281338389
více2177194801314971117166
než23601948013158110152
15%mužů2529194801315497187294349391447
s8502098013140
OAB9072098013173131184
v11082098013149
EPIC11742098013150101120180
trpělo1376209801312958117168189244
UUI16372098013168133153
a18072098013150
téměř1879209801312877163214242
30%21382098013153103194
trpělo2354209801312858116168188244
jakoukoli2620209801311864107162218261315336356
formou850224801312985116205262319
UI.1191224801316990108
Současná13212248013151108165212260299355403
studie1747224801314073130188209261
proto2030224801316091147178233
nemusí22852248013159111199255293313
být26202248013161107143
plně2785224801316183139191
reprezentativní320389801313385145176228273324383414464496518567626648
pro3874898013169101158
typičtější405689801314293154177225261312333372393
populaci4473898013169128189247269318366388
v4885898013157
reálném496689801314192140162220273363
světě3203104801314088138168217
s34371048013140
vyšší3494104801314999137174194
úrovní3705104801315786140186243263
inkontinence3990104801311772115170226255276331381437483532
a45381048013150
větší4604104801314999130169188
míroumužů.48091048013189109138192247353408450505520
ZÁVĚR32051458018183179257334416
Studie3203179801315080136194215266
ukazuje34881798013157101151194250272323
statisticky3830179801314073121152173211245266312356406
významné42551798013149100145202250336393444
zlepšení4718179801314465117175213265321342
téměř5083179801312979165217246
všech3203194801315090143192249
hodnocených34731948013159117177235293342393450496544601
parametrů.40951948013160110141191280333366397455472
Podle45871948013156111171193246
výsledků48531948013150102142164217277322380
je5257194801312072
solifenacin32032098013141100124145174227285335384406464
vhodným36922098013158117176237296342433
léčivem4150209801313185135157206259349
pro45232098013169102159
pacienty,47062098013170120169192245303335387401
kteří5131209801315592144175198
selhávají3203224801314194117174223270320342364
při3591224801316193115
léčbě3730224801312376126185239
jiným3993224801312345103149239
antimuskarinikem.42562248013150108139161250307347392442474496554576621672761780
LITERATURA852268401475992157220291371428510580661
1.850284601335673
Abrams9492846013367129165218309351
P,1325284601335968
Kelleher14182846013360114139164219280335371
CJ,18142846013364107128
Kerr19672846013360113149185
LA,21772846013352121146
Rogers23482846013359119181236272316
RG.26892846013359130154
Overactive28702848013174125176208258306343365414466
bladder3362284801316084132192251304335
significantly3721284801314365124181203229256304354412443466514
affects4259284801315281110162212248290
quality45752848013159117165188209242294
of4895284801315887
life.500628480131254675127144
Am51762848013164153
J8502998013138
Manag9122998013186135193241301
Care.12372998013163112144195212
2000;14732998013154105161216234
617312998013154
(111809299801312976117
Suppl):19502998013151108168228251279296
S580–590.22702998013151102154208266317366420438
2.850314601335679
Coyne9583146013364122172234289
KS,12753146013360116139
Matza14423146013389142177226280
LS,17453146013358113135
Thompson19033146013360122182273335378438499
CL,24313146013364114137
Kopp25973146013360118181243
ZS,28683146013361116138
Khullar30353146013359121181206231284319
V.3382314601336278
Determining34893148013171125158209240330352410431489548
the4061314801314098151
importance42363148013128117176235267305354412460511
of4771314801316493
change48883148013154112161218278331
in5243314801312885
the850329801313492145
overactive10193298013159107159190240289325347396448
bladder1491329801316184133192252304336
questionnaire.18513298013160117170210244266324383440489511542594611
J24863298013138
Urol.25483298013169100156179198
2006;27703298013153105160214232
176(2):3026329801315397145173224250267
627–632.33173298013154104154203259310359377
3.850344601335778
Irwin952344601333470154180241
DE,12243446013374128151
Milsom14073446013388114140182243335
I,1766344601333457
Hunskaar18553446013372132193236287341394430
S,2308344601336285
et2417344601336399
al.2540344601336187109
Population‑based26733448013164120180239261310343365423482516577627668721782
survey34793448013149106138191243291
of3794344801316796
urinary3914344801316799121179229260312
incontinence,4251344801313189138194253285307365419477526577594
overactive48693448013167116168200250299336358407460
bladder,850359801316184132192251304336349
and12203598013150107167
other1408359801315891149202233
lower1665359801312078157209240
urinary1926359801315990112170219250302
tract2252359801313162112161197
symptoms2473359801313887178237270326416455
in2952359801312077
five3050359801312754103155
countries:32253598013150105163221253285307360400418
results3667359801312981121177199233274
of3962359801315987
the4073359801313189142
EPIC42363598013151105125188
study.4448359801313872130189238251
Eur47203598013151106137
Urol.48783598013169100156180198
2006;50973598013153105160214232
50(6):8503748013154105134184211227
1306–1314.1101374801315499151205263309354400447464
4.850389601335677
Abrams9463896013367128163215304346
P,1310389601335867
Artibani13963896013367101139163224276336360
W,17753896013392109
Cardozo19023896013363115150210269314372
L,2293389601335174
et2386389601335490
al.249538960133527798
Reviewing26143898013155107155177228306327384442
the3080389801312986138
ICS3242389801311980130
200233923898013153103157206
terminology3621389801313080110199220276334356413472520
report:4164389801312879137195226263281
the4469389801312986138
ongoing46273898013158115173230252308367
debate.50133898013159111170219250300317
Neurourol8504048013170123181212269327358414437
Urodyn.13114048013169100157217265324343
2006;16784048013154106161215232
25(3):19344048013154107133184208225
293.21834048013154105155172
5.850419601335677
Abrams9514196013367129165218309352
P,1326419601335968
Cardozo14174196013364117152214274319379
L,1820419601335175
Fall19184196013354102128153
M,20944196013389113
et2230419601335591
al.2345419601335378101
The24714198013151111164
standardisation2659419801314176126183243291323381402441492524546604662
of3345419801315987
terminology3456419801313485117207229286344367425486534
of4014419801315987
lower4126419801312381159211243
urinary4393419801315890112170219250302
tract4719419801313466116164200
function:4943419801312988146195231253311369386
report850434801313284144203235272
from1146434801312962118208
the1378434801313492145
Standardisation1547434801315283132190249298329387409448498530553610669
Sub‑committee22404348013151108167202254310399488510543580631684
of2949434801315887
the3060434801313492145
International3229434801312381113164195254303335357415473522544
Continence37974348013163119178209232289342400449500
Society.43214348013151109159180233266317331
Neurourol46764348013170123181212269326358414437
Uro‑5138434801316899156191
dyn.8504498013160108167186
2002;10604498013154105160210227
21(2):13124498013153100122173199216
167–178.15524498013154100150198245288339358
6.850464601335679
Wagg9514646013393144205266
A.1239464601336893
Persistence13554648013155106137178199238273324382430481
with18594648013180102135194
medication20764648013190143203225273323355377435493
and25924648013150108167
overactive27824648013159107159190240289325347397448
bladder:3253464801316184133192252305336356
an36324648013150108
ongoing37634648013158117176234256314373
challenge.41594648013149107156178200253310370423440
Expert46224648013151100160215246283
Rev49284648013155109157
Phar‑51084648013156112161192221
macoecon8504798013190139188244298347403461
Outcomes13364798013173132165212268357410451
Res.18114798013155108149168
2016;20034798013154105153200217
16(4):22444798013154100128178203220
475–481.24884798013154102151206263317365378
7.850494601335668
Chancellor9414946013364124176236285339365390450486
MB,14504946013389148171
Zinner1644494601336186146206261297
N,1964494601337396
Whitmore20834946013393154179215306366402457
K,2563494601335985
et2671494601335592
al.2786494601335379101
Efficacy2911494801315177105133182232280331
of3266494801315987
solifenacin3377494801314199122144172224282331380402459
in3860494801312381
patients39654948013161110143165217275307349
previously4338494801316092144193216273331371393440
treated4803494801313465117165197248308
with51354948013180102136194
tolterodine850509801313490113146197229285346367425478
extended13515098013153101137188246305358419
release1794509801313182105157206245298
421155098013154
mg:21885098013190149167
results2379509801313182122179201234276
of2677509801315987
a27875098013150
12-week,2859509801315498128208260314359381
multicenter,32625098013190147169203225273324382414465496509
open‑label,37945098013158118172230264288336396450473490
flexible‑dose4306509801312754107154177236259312347408466506560
study.4890509801313974131191239253
Clin5165509801316385106164
Ther.8505248013151111164196210
2008;10845248013153105160214231
30(10):13395248013154106135182229256273
1766–1781.1636524801315498145200257304347398446458
8.850539601335680
Chapple9585396013363123176237300326381
CR.13675396013363121146
Solifenacin15385398013156114137159187239297346394416474
provides2040539801316193150198221280333373
effective2437539801315887117169218254277326378
antimuscarinic28395398013154112144166255312351400449481503561583631
therapy3494539801313997150181231290338
for3856539801313390122
the4002539801313997150
complete41765398013154110200259282335368419
management46245398013190139196245305358447500558589
of5242539801315987
overactive8505548013159107159190240289325347396448
bladder.1322554801316184132192251304336350
Expert16965548013151100161215246283
Opin20035548013174135157215
Pharmacother.22425548013155112161192282331379435468526579610624
2006;28905548013154106161215232
7(17):3146554801315478125169198214
2421–2434.33845548013154102151198247295343392445463
9.850569601335676
Robinson9495696013367127189215275318378439
D,1419569601337493
Cardozo15435696013364117152213274319379
L.1945569601336085
Solifenacin:20545698013159117141162191243301350398420478495
pharmacology25735698013168127176207297346395451474532592641
and32385698013158116175
clinical3438569801315779100158180228278300
efficacy.3762569801316188116144193243292342356
Expert41425698013160109169223255292
Rev44585698013164117166
Clin4648569801317092114171
Pharmacol.48435698013164120169201291340388444467486
2009;8505848013154105160214232
2(3):1106584801315479130154171
239–253.13015848013154107157214261314364382
10.8505996013356107129
Chancellor10035996013364124176237286339365390450486
MB,15145996013388148170
Yehoshua17085996013360108169229272332392444
A,2177599601336792
Waweru22935996013393143222276312373
C,2690599601336488
et2802599601335692
al.2918599601335379101
Limitations3044599801315073161183217266298320378437476
of3545599801315987
anticholinergic36565998013151109141163211269327350372429482514572594642
cycling43225998013150101148171192250309
in4655599801312482
patients47625998013161111143165217275307349
with51365998013179102135193
overactive8506148013159107159191241290327349398451
bladder1325614801316992141201261314346
(OAB)16956148013137108169224250
with19786148013179102136194
urinary2196614801316799121179228260312
incontinence2532614801313189138194253285308365419477526577
(UI):31336148013138105128156172
results3330614801314092133189212245287
from3641614801313771127218
the38836148013142100154
CONsequences40616148013171141211250304364422475533582633674
of4759614801316795
Treatment4879614801315984136184216306360418450
Refractory8506298013156109137170220268304360392444
Overactive13186298013174125177208258307343365414466
bLadder18086298013161110161220280332364
(CONTROL)2196629801312989158228280336409458486
study.2706629801314176134193241255
Int2985629801312381113
Urol3122629801316999156179
Nephrol.33256298013170123183242273329353371
2016;37206298013154105153200217
48(7):39616298013154108136189218234
1029–1036.42206298013153100150201259305352402454473
11.8506446013356100116
Desroziers9856446013373128170204263308333387422465
K,1469644601335984
Aballéa15726446013367128180205229283335
S,1926644601335475
Maman20206446013388140230282341
K,2380644601335984
et2483644601335590
al.2592644601335378100
Estimating2711644801315191125147234282314336392451
EQ-5D31816448013151123157208275
and34756448013150107165
OAB-5D36606448013173133186220270337
health40176448013158110158179212269
state4306644801314074123154205
utilities4530644801315891112134155187209261300
for4854644801312481112
patients49866448013160109140162214271302343
with8506598013179102135193
overactive10676598013159107159190240289325347397448
bladder.1539659801316184133192252305336350
Health19136598013170123171193226284
Qual22216598013174132181203
Life2448659801315072100152
Outcomes.26246598013174133166213268358411452471
2013;31196598013154105153198213
11:3357659801315394105
200.34866598013154105160178
12.8506746013356104127
Irwin1001674601332662145171231
DE,12566746013373127150
Kopp14296746013360119181244
ZS,16966746013361116138
Agatep18586746013367127179215268331
B,2212674601336082
Milsom23186746013388114139182242334
I,2675674601332649
Abrams27486746013367130165218309352
P.3124674601335868
Worldwide32166748013190145177200260338361420473
prevalence3713674801316193144193243265318376425475
estimates4213674801315393128150239288320371411
of4648674801315987
lower4759674801312482160212244
urinary5027674801315990112170219250302
tract850689801313466116164200
symptoms,1075689801314695186245278334424463482
overactive15816898013164112164195245294330352401453
bladder,2064689801316084132192251304335349
urinary2437689801316495117175224255307
incontinence2768689801312886135190249281303360413471520571
and33636898013155113173
bladder3565689801316184133192251304336
outlet39256898013164122155178231264
obstruction.42136898013164124164199230289337373395453512531
BJU4768689801316197165
Int.4957689801312987119138
2011;51196898013159111158199210
108(7):8507048013154101155183235264281
1132–1138.1155704801315394139188239286326371423442
13.8507196013356105126
Pavesi9967196013359110161215258282
M,12987196013389113
Devlin14317196013373129181207231292
N,1743719601337295
Hakimi18587196013372125176203294319
Z,2197719601336184
et2301719601335591
al.2413719601335378100
Understanding25347198013169126186239270311345395453512534592651
the3209719801313189142
effects3372719801315382112164213249291
on36847198013158117
HR‑QoL38227198013169123156233292341
of4184719801315887
treatment4295719801313162114162194283337394426
for4745719801312683115
overactive48817198013158107158190240288325347396448
bladder:850734801316184132192251304336355
a12307348013149
detailed13047348013159112145195217239292352
analysis16807348013150108156179227267288327
of2031734801315987
EQ-5D21427348013152124160211279
clinical244573480131497193150172220270292
trial276173480131346689137159
data29447348013160109141191
for3159734801312886118
mirabegron.33017348013190112143193252306367398455513532
J38577348013138
Med39197348013186139199
Econ.4142734801315199155213232
2013;43987348013154105153198213
16(7):46367348013153100128180209226
866–876.48867348013153107161219274324372391
14.8507496013356105127
Coyne9967496013364122172233287
KS,13037496013359115137
Wein14597496013393144169229
AJ,17077496013367111132
Tubaro18587496013354107168221256315
A,2192749601336792
et2303749601335591
al.2413749601335378100
The25347498013151110163
burden27177498013160118149206259316
of3053749801315886
lower3163749801312077155206237
urinary3420749801315989112169217248299
tract3743749801313062111159195
symptoms:3958749801314190179238271326415454472
evaluating44507498013153101150172229277309331388447
the4921749801313087140
effect5081749801315381111162212247
of850764801315987
LUTS9587648013149114166217
on11967648013158117
health‑related13347648013159112160182215273307340391414462495546606
quality19617648013159117165188209242294
of2276764801315887
life,238776480131204170122139
anxiety25477648013150107155177230263314
and28827648013150108167
depression:30707648013160113173205256296336357415474491
EpiLUTS.35827648013151110133181245297348367
BJU3970764801315692160
Int.4154764801312178110129
2009;43047648013154105160214232
103(Suppl45577648013154101151177225282341401425
3):500376480131537895
4–11.51197648013153110156197210